← All trials
NCT05340153
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 11, 2022
- Primary completion
- Dec 31, 2022
- Completion date
- Dec 31, 2022
- First posted
- Apr 22, 2022
- Last posted
- Apr 22, 2022
- Enrollment
- 184
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of YaoundeLead sponsor
- University of YaoundeCollaborator
- University of YaoundeOverall official - principal investigator
- University of YaoundeReponsible party - principal investigator
- Government of CameroonCollaborator
- Association Camerounaise pour le Marketing Social (ACMS), CameroonCollaborator
- Impact Malaria, CameroonCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.